Mason Carrico
Stock Analyst at Stephens & Co.
(3.07)
# 1,368
Out of 5,046 analysts
75
Total ratings
43.94%
Success rate
2.53%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $73.91 | +2.83% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $9.77 | +12.59% | 2 | Sep 2, 2025 | |
| NTRA Natera | Reiterates: Overweight | $183 | $198.93 | -8.01% | 5 | Aug 15, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $35.06 | +91.10% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $123.54 | -15.01% | 8 | May 20, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $1.8 | $2.34 | -23.08% | 5 | May 15, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $13.64 | +2.64% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $15.02 | +166.31% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $88.07 | +30.58% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $36.08 | +24.72% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $93.02 | -40.87% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $3.90 | +53.85% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $25.87 | -34.29% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $47.95 | +8.45% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $8.04 | +148.76% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $25.50 | +60.78% | 7 | Jan 2, 2025 |
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $73.91
Upside: +2.83%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $9.77
Upside: +12.59%
Natera
Aug 15, 2025
Reiterates: Overweight
Price Target: $183
Current: $198.93
Upside: -8.01%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $35.06
Upside: +91.10%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $123.54
Upside: -15.01%
Pacific Biosciences of California
May 15, 2025
Reiterates: Overweight
Price Target: $1.8
Current: $2.34
Upside: -23.08%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $13.64
Upside: +2.64%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $15.02
Upside: +166.31%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $88.07
Upside: +30.58%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $36.08
Upside: +24.72%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $93.02
Upside: -40.87%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.90
Upside: +53.85%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $25.87
Upside: -34.29%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $47.95
Upside: +8.45%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $8.04
Upside: +148.76%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $25.50
Upside: +60.78%